Lilly, Roche Join Forces to Fight Alzheimer's

Posted: Updated:
A diagnostic that detects Alzheimer's earlier means drugs currently in development could slow progression of the disease. A diagnostic that detects Alzheimer's earlier means drugs currently in development could slow progression of the disease.

On its surface, the recent partnership between Indianapolis-based giants Eli Lilly and Company and Roche Diagnostics may look like a standard big-business arrangement, but executives say it’s much deeper—and could revolutionize how Alzheimer’s Disease is diagnosed. Detecting the devastating illness is more complicated than it may seem, because other diseases with similar symptoms must first be ruled out. By working together to create a better diagnostic method, millions of patients could slow Alzheimer’s progression—before its trademark mental decline.

Diagnosis of Alzheimer’s relies largely on noticed memory or mental decline, but when this symptom surfaces, the disease has already progressed to a moderate or severe stage. The only way to definitively diagnose Alzheimer’s is to detect the presence of tau tangles or amyloid, which is plaque, in the brain. A recent technology allows doctors to do this; tracers are injected that bind to amyloid and “light up” in an image of the brain.  

Of the three tracers on the market, Lilly owns one, called Amyvid. However, patients must live close to a manufacturing facility, because it biodegrades quickly after production. As result, a sizable population of patients are missing out on this method.

Lilly and Roche are now combining efforts to develop an alternative test to detect amyloid. Because amyloid is free-floating in the body, Lilly Vice President of the Global Alzheimer’s Platform Team Phyllis Ferrell says it can also be detected in spinal fluid.

“In clinical research, we draw that spinal fluid and are able to do a lab test, kind of like you do a cholesterol test,” says Ferrell. “You run it through a test and it comes back positive or negative. We’re working with Roche to take this research tool and make it commercially available, so that the ability to detect amyloid can be done much more broadly than today.”

Lilly says detecting Alzheimer’s earlier is a critical factor for the drugs that are currently in development.

“You have to catch someone much earlier in the disease than we’re catching them right now,” says Ferrell. “We want to make it as simple and easy as possible to detect this pathology.”

It also makes good business sense for Lilly, because it owns one of tomorrow’s potential disease-modifying therapies: solanezumab, which aims to destroy amyloid buildup in the brain. Currently in Phase 3 human clinical trials, it could be a breakthrough drug for Alzheimer’s patients. In the most recent study, it showed better results among patients in the earlier stages of the disease. Logically, sales of solanezumab will be better with easier—and earlier—Alzheimer’s detection.

“We want to have [the diagnostic] available at the time of a potential solanezumab launch,” says Ferrell. “We think there’s benefit to patients and their families to know as soon as possible. If you’re trying to slow the progression of the disease, the best way to do that is to detect and treat it early.”  

Roche says its expertise in developing such large-scale diagnostic “kits” would make the test rapidly scalable. 

“We are the leading diagnostic company, so that means we have more instruments and more technology in more labs than any other diagnostic player; patients are never too far away from a lab that can run the test,” says Roche Companion Diagnostics International Business Leader Bruce Jordan. 

“It’s our instrumentation already available today that allows us to place new and innovative kits into an already existing hospital laboratory.”

Because the spinal fluid diagnostic involves taking something out of the body—rather than putting a drug in—it will have a faster regulatory path, making Lilly and Roche certain that their teamwork could soon break new ground in how doctors find, and ultimately treat Alzheimer’s disease.

Jordan says Roche is hopeful a spinal fluid diagnostic could be less expensive than the current method that involves brain imaging.
Ferrell says, with current diagnostic methods, valuable time is lost in slowing the progression of Alzheimer’s.
Ferrell says a spinal fluid diagnostic test will make it easier for doctors to detect Alzheimer’s with certainty.
  • Perspectives

    • The First Thing Nonprofit Boards Should Focus On: Member Engagement

      There is no shortage of literature on how to run a nonprofit and what the board of directors should be doing. Do a quick search for “grant writing advice” or “board meeting agenda” and you will easily find hundreds of resources. But if there is so much helpful information around, why is serving on a nonprofit board sometimes so draining? After founding two nonprofits, Musical Family Tree and the Speak Easy, as well as serving on several nonprofit boards...



  • Most Popular Stories

    • (photo courtesy The Times of Northwest Indiana)

      Hammond Pulls 135 Jobs from Illinois

      A Hammond factory recently vacated by Michigan-based Lear Corp. didn’t sit empty for very long. Midland Metal Products has taken over the former seat factory, having relocated from Chicago after 95 years. 

    • (photo courtesy of TriCore Logic)

      Fort Wayne IT Firm Expanding

      TriCore Logic has announced plans to expand its office space and staff at its downtown Fort Wayne headquarters. The company plans to invest over $200,000 in the expansions. The 2010-founded company moved to the Anthony Wayne building in 2013, and now plan to grow their staff of five employees by up to eight over the next four years. 

    • ‘Transformation’ Continues in Westfield

      Indiana’s fastest growing city is showing no signs of slowing down.  Mayor Andy Cook says now that Westfield has established itself as a destination for family sports with the Grand Park Sports Campus, the $35 million Grand Junction Plaza will transform the city’s downtown into a destination, a place “where people want to be.”   Cook says the project, more than a decade in the making, is an example of a place making strategy necessary for Midwest...
    • (courtesy Wes Mills)

      Purdue: Farmland Values Decline Fifth Straight Year

      The value of top-quality farmland in Indiana has declined continuing a five-year trend, according to the latest data from Purdue University.  The statewide average of the best cropland is $8,212 per acre, down more than five percent, or $456 per acre, from the same period last year. Purdue’s survey shows average and poor-quality farmland values also dropped, but not as much. Average quality farmland declined by 0.9 percent. Purdue says the poor...

    • (Image courtesy of Horseshoe Casino Hammond.)

      Indiana Casinos to Begin Sports Betting

      A pair of northwest Indiana casinos will soon add sports wagering to their offerings. Horseshoe Hammond Casino and Ameristar Casino East Chicago are both set to open sports betting areas at their respective casinos ahead of the kickoff to the 2019 NFL season.